BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 15, 2021
View Archived Issues
Immune response research shows GM-CSF plays role in COVID-19 severity
Read More
Many elite controllers at HIV's ground zero
Read More
Targeting membrane protein starves pancreatic tumors
Read More
Henlius initiates dosing in phase II/III study of HLX-10 plus bevacizumab in first-line mCRC
Read More
Chinese researchers disclose SCN10A blockers
Read More
Hunan Warrant Pharmaceuticals patents Bcr-Abl1 and/or BTK inhibitors
Read More
Inflazome synthesizes new NLRP3 inflammasome inhibitors
Read More
Galapagos presents TYK2 inhibitors
Read More
Successful completion of IND-enabling rodent toxicology studies with R-107
Read More
The Feinstein Institute for Medical Research divulges tetranectin-targeting antibodies
Read More
GSK-3640254 demonstrates safety and dose-antiviral response relationship in phase IIa trial
Read More
ALG-097111: targeting 3CLpro for treating SARS-CoV-2
Read More
E-2027 improves cognitive function in mouse model of AD
Read More
Inhibrx identifies MTD of INBRX-105 in first-in-human study in solid tumors
Read More
I-SPY COVID trial drops apremilast for futility
Read More
DARPins as promising mutation-resistant antivirals for potential SARS-CoV-2 treatment
Read More
Tilt advances phase I trial of TILT-123 in metastatic melanoma
Read More
New phase II trial investigates Tedopi with Keytruda for recurrent ovarian cancer
Read More
Phase III trial of Libtayo in advanced cervical cancer stopped early for favorable OS data
Read More
Helixmith initiates phase II study of Engensis in ALS
Read More
Improved delivery observed for ABL-301 in mouse models of PD
Read More
IFN-mediated NAD depletion by upregulation of PARP9/10/14 sensitizes PDAC cells to NAMPT inhibitors
Read More
NSD3 drives oncogenesis in LUSC, but may sensitize these tumors to bromodomain inhibition
Read More
Boehringer Ingelheim ends phase II trial of BI-764198 for COVID-19-related ARDS
Read More
SiteOne initiates phase I study of ST-2427 in healthy volunteers
Read More
Rubius reports initial data from phase I/II study of RTX-240 in advanced solid tumors
Read More